Beyond Air, Inc.

The company is headquartered in the United States and manages invoicing and cash collection from Garden City, New York, with a central warehouse in Atlanta, Georgia. Commercial activity is currently concentrated in the U.S., where management specifically cited additional hospital contracts as the driver of revenue growth. Manufacturing is outsourced to third-party partners, including Spartronics and Medisize in Ireland, which makes supply continuity dependent on external production capacity. Beyond Air also maintains subsidiaries and development entities in Israel, Ireland, Australia, Cyprus, Bermuda, and the U.S., reflecting a geographically distributed R&D and corporate structure. The company is also pursuing global expansion through commercial partnerships, which increases exposure to regulatory, reimbursement, and logistics differences across markets.

Beyond Air faces significant going-concern and financing risk because it continues to generate losses and has stated that additional funding will be needed within one year. Commercial execution risk is also high because the company has limited experience selling medical devices at scale and must build a sales force and reimbursement pathway while competing against larger, better-funded rivals. Supply chain and manufacturing risk is meaningful because production is outsourced to third parties, and the company depends on contract manufacturers and logistics providers to deliver devices and consumables. Regulatory and clinical risk remain central because pipeline programs such as Beyond Cancer and NeuroNOS have not yet been approved and may never reach commercialization. The business is also exposed to cybersecurity, geopolitical, and natural-disaster risks because it handles protected health information, relies on IT systems, and depends on a global supply and distribution network.